Tempus ECG-AF vs Viz HCM

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Tempus AI, Inc.
VS
by Viz.ai

AI Verdict

Tool A is designed for proactive risk assessment of future atrial fibrillation in older adults, leveraging ECG analysis to identify at-risk patients for earlier follow-up. In contrast, Tool B focuses on the real-time detection of existing hypertrophic cardiomyopathy via ECGs and streamlines care coordination for diagnosed patients. While both utilize AI for ECG analysis in cardiology and share similar reimbursement pathways, they address distinct cardiac conditions and clinical needs.

Choose Tempus ECG-AF if…

Choose Tempus ECG-AF if your primary objective is to proactively identify patients aged 65 or older who are at an increased risk of developing new-onset atrial fibrillation within the next 12 months. This tool is ideal for integrating into routine ECG analysis workflows to support earlier identification and follow-up for AF prevention in a specific, at-risk demographic.

View Tempus ECG-AF →

Choose Viz HCM if…

Choose Viz HCM if your institution requires real-time detection of suspected Hypertrophic Cardiomyopathy (HCM) from ECGs and robust, AI-powered care coordination. This tool is best suited for streamlining the diagnostic pathway and automatically directing patients to appropriate specialists, significantly reducing time to diagnosis and treatment for HCM.

View Viz HCM →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Tempus ECG-AF Viz HCM
Pricing Contact vendor Unknown
Deployment Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. Unknown
BAA Available Yes AI-estimated Yes AI-estimated
FDA Status Yes AI-estimated Cleared AI-estimated
HIPAA Yes AI-estimated Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Viz HCM

Viz HCM offers a cloud-based platform with mobile-based alerts and seamless integration into existing clinical workflows, EHR, and PACS systems, including specific EMR integrations with Epic and Cerner. In contrast, Tempus ECG-AF explicitly states it does not have a dedicated user interface, which limits direct clinician interaction and workflow integration.

Clinical Value

Viz HCM

While both are FDA-cleared and address significant cardiac conditions, Viz HCM focuses on real-time detection of Hypertrophic Cardiomyopathy (HCM) and actively coordinates cardiac care, significantly reducing diagnosis and treatment time for a critical condition. Tempus ECG-AF predicts the risk of Atrial Fibrillation (AF) within 12 months, which is valuable for earlier identification, but Viz HCM's impact on immediate care coordination for HCM, a leading cause of sudden cardiac death, suggests a more direct and potentially life-saving clinical impact.

Pricing & Value

Tie

Both tools have identical CMS reimbursement available for CPT codes 0764T and 0765T, with a Medicare rate of $128.90 effective January 1, 2025. Neither tool provides specific pricing details beyond 'contact vendor' or 'subscription-based,' making a direct comparison of overall cost-effectiveness impossible with the given information. Therefore, their value propositions from a reimbursement standpoint are equal.

Enterprise Readiness

Viz HCM

Both tools are FDA-cleared, HIPAA compliant, and provide BAAs, which are essential for enterprise use. However, Viz HCM's explicit mention of a 'Cloud-based platform' and 'seamless integration with existing clinical workflows, EHR, and PACS systems,' including integrations with leading EMRs like Epic and Cerner, indicates a more modern and robust enterprise deployment strategy. Tempus ECG-AF's description of integration into 'healthcare facility systems' is less specific regarding scalability and depth of integration.

Innovation

Viz HCM

Both leverage AI for ECG analysis, which is innovative. Tempus ECG-AF's innovation lies in predicting future AF risk. However, Viz HCM extends its innovation beyond detection to include real-time alerts, mobile notifications, and automated direction of patients to appropriate care specialists, actively streamlining the entire care coordination workflow. Viz HCM also highlights being the 'only approved HCM algorithm on the market,' showcasing a unique market position.

Support & Docs

Viz HCM

Viz HCM offers a publicly accessible 'Knowledge Base' with common questions, troubleshooting guides, and product overviews, demonstrating a structured approach to support documentation. Tempus ECG-AF provides contact information for its support team but does not explicitly detail a public knowledge base or extensive self-service documentation.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Tempus ECG-AF Viz HCM
Tool Name Tempus ECG-AF Viz HCM
Company Tempus AI, Inc. Viz.ai
Primary Use Case Identifies patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months. Detects suspected Hypertrophic Cardiomyopathy (HCM) and coordinates cardiac care.
Target Patient Population/Criteria Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery. Not specified
Key Technology AI-based algorithm for 12-lead ECG analysis AI-powered ECG analysis
Reimbursement CMS reimbursement available (CPT 0764T and CPT 0765T to APC 5734, Medicare rate of $128.90, effective January 1, 2025). CMS reimbursement available for CPT codes 0764T and 0765T (national payment rate $128.90, effective Jan 1, 2025).

Videos

Demos, reviews, and walkthroughs featuring Tempus ECG-AF and Viz HCM.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Tempus ECG-AF is an AI-based algorithm that analyzes 12-lead ECGs to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months. Viz HCM is an FDA-cleared AI tool that uses real-time ECG analysis to detect suspected Hypertrophic Cardiomyopathy (HCM).
Tempus ECG-AF is intended for patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery. Viz HCM is approved for use on adult patients (18 and up) to identify those for further follow-up for hypertrophic cardiomyopathy, but it is not intended for use on patients with implanted pacemakers.
Tempus ECG-AF is a software solution integrated into healthcare facility systems with advanced cardiology algorithms. Viz HCM is a cloud-based platform that integrates into hospital IT systems, including EHR and PACS, and offers seamless integration with existing clinical workflows.
Tempus ECG-AF supports earlier identification and follow-up for AF risk, with results interpreted in conjunction with other diagnostic information and clinical history. Viz HCM provides mobile-based alerts and notifications to multidisciplinary care teams, automating the direction of patients to appropriate care specialists, and streamlining cardiac care coordination.
Tempus ECG-AF is compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems. Viz HCM integrates with existing clinical workflows, EHR, and PACS systems, and analyzes all 12-lead ECGs throughout the health system.
Both Tempus ECG-AF and Viz HCM have CMS reimbursement available for CPT codes 0764T and 0765T. The Medicare national payment rate for these codes is $128.90, effective January 1, 2025.

Backers

Who funded each tool's parent company.

AI Tool Finder
AI-powered search. Results may not be comprehensive.